• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去)

    [复制链接]
1265570 1620 老马 发表于 2011-10-27 08:05:18 | 置顶 |
老马  博士一年级 发表于 2012-4-27 18:50:42 | 显示全部楼层 来自: 浙江温州
Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type1 h9 @0 F3 t0 r  Z9 P, a: A$ ~# S1 ~
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
) R1 t. M9 M+ @) I, V4 n+ Author Affiliations6 T1 w$ F" B3 R
' Q9 x. a- D1 X' W" A1 q* s, t+ ?
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan ) x' _( I+ i+ c. g4 G  ~% t) J
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 7 h$ S- G  c% P; F; q
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan * _" b5 h  q. G% D
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
+ d/ d* s& ?0 A5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
; s$ o5 Y8 D+ D8 g+ F' s6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
  p/ C5 ?% o' b  _8 e7Kinki University School of Medicine, Osaka 589-8511, Japan 0 H3 d  B1 W/ \+ z6 S
8Izumi Municipal Hospital, Osaka 594-0071, Japan 2 |9 M1 L9 a, I/ n6 S5 h' n9 a
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan & [" n" @0 R' q0 p
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
- \/ g% M6 c: E# z* l3 cAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
! L6 g( l' c8 j5 {# b! e, [: A8 r3 B
6 t4 x. E/ m6 Z9 I7 l. L
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:52:43 | 显示全部楼层 来自: 浙江温州
S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type
7 F2 L( _3 O' i+ ~' ]$ t( C2 f2 p9 ~& m7 ]- \$ g  T
Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato % b4 u  ]0 j4 v0 s" r: \

' d0 O  K+ g$ f. V; fAffiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  
+ k; ^/ b0 ]( W  C* n8 b9 g
) ^* X" J' {) q) N4 @. w7 ^; wPublished online on: Thursday, December 1, 2011
( ]" g' F2 q6 a/ F; W8 s2 d
3 S" H+ O. a% ~Doi: 10.3892/ol.2011.507 6 G. ^4 J  K2 [) X0 H/ f
' C  ~4 z7 U  a& d- D
Pages: 405-410 5 X+ }4 r$ U/ B. X$ F' U7 G
! O% g; y4 G, }# Y3 h' y/ W
Abstract:
4 Y: S( T. r7 Y, i2 Y: K9 TS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.* r, w' l; ~2 P6 J

4 J5 J8 ?/ U) b$ [1 \7 z9 E
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-27 18:57:27 | 显示全部楼层 来自: 浙江温州
Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population, h7 b9 n! F/ ?$ {, K
F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3 1 m3 T$ c8 R. e0 r$ z- l% T
+ Author Affiliations0 t2 H; p4 U1 N* t! [; H
1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu * W. W" Z* M5 K' f' G) ^+ r8 S, l- f4 U
2Department of Thoracic Surgery, Kyoto University, Kyoto ( c) j& m; _% e- a, p( ]' Q
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
3 l0 m% [+ g  i, S! e6 x8 R% L&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
, W9 t: Y$ u" `8 E/ N2 B" r. zReceived September 3, 2010. / k, C) t6 v9 s8 |" M
Revision received November 11, 2010. & _8 h% g5 S' ]7 ?7 U! b6 X2 X
Accepted November 17, 2010. ; W9 y# I" }% E/ u8 B( G
Abstract9 {0 o- ?. ^  g- J" z" Y2 R
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
( @! O$ k; x8 u# |1 _- O; F9 r5 L, `1 ?5 C' TPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
1 A% O& |* L/ _  }( S, c# SResults: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
5 |  h2 u) @. N; C" J* j" yConclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study. ; N3 f8 e6 ~( I) {5 y
个人公众号:treeofhope
走在异乡  高中一年级 发表于 2012-4-28 00:30:22 | 显示全部楼层 来自: 四川成都
一直关注老马的帖子,前方的指明灯。祝福你爸好疗效
累计签到:1 天
连续签到:1 天
[LV.1]初来乍到
baiselianyi  初中二年级 发表于 2012-4-28 10:24:44 | 显示全部楼层 来自: 浙江台州
一直得到老马帮助,祝福老马爸爸
老马  博士一年级 发表于 2012-4-28 18:00:37 | 显示全部楼层 来自: 浙江温州
26日吃了12片地米(0.75mg一片),27日吃了22片地米(0.75mg 一片),28日吃了12片地米(0.75mg一片),都分二次吃。
" B7 y& O7 ]& U  [  i; y( @  p1 u% X今天为止没有任何反应,每天吃VC,VB2,还有漱口水,就怕口腔溃疡。
个人公众号:treeofhope
bishop_cn  大学一年级 发表于 2012-4-28 23:16:11 | 显示全部楼层 来自: 中国
副作用如何,单药反应很小吧?7 [5 Y* p  w# J
老马  博士一年级 发表于 2012-4-29 00:20:00 | 显示全部楼层 来自: 浙江温州
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy; ^# J0 p/ Y: X5 i2 O$ [' n
http://clinicaltrials.gov/ct2/show/NCT01523587. F) N$ t8 `! M( w# l

$ S7 [  A( e. S; L* e( QBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
- Y6 o* Z2 H8 F3 ^http://clinicaltrials.gov/ct2/show/NCT01156545
个人公众号:treeofhope
老马  博士一年级 发表于 2012-4-29 20:53:58 | 显示全部楼层 来自: 浙江温州
本帖最后由 老马 于 2012-4-30 09:33 编辑 $ C6 U+ [' _2 ], f+ w: k) e% B, W
# W6 P5 j- k' Z5 a( q% ]' C1 a2 ~
从4月24日开始到4月28日,打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。$ ~9 s/ d( @7 E/ ~9 h
至今为止,未出现化疗副作用。
个人公众号:treeofhope
英雄武松  大学四年级 发表于 2012-4-30 01:37:05 | 显示全部楼层 来自: 哈萨克斯坦
老马 发表于 2012-4-29 20:53 7 _0 D, Y$ w" J5 a( Y" O$ @
从4月24日开始到4月28日,打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。1 h0 m) w3 Q( V! k# y6 i( O
至今为止,未出 ...
/ K; w# U# a' R( G# _! T& e
没有副作用是第一追求,效果显著是第二追求。
' {7 N! p5 s: v不错。

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表